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Summary
Anaemia is associated with a reduction in quality of life, and is common in patients with colorectal cancer . We
recently reported the ﬁndings of the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial
comparing haemoglobin levels and transfusion requirements following intravenous or oral iron replacement in
anaemic colorectal cancer patients undergoing elective surgery. In this follow-up study, we compared the
efﬁcacy of intravenous and oral iron at improving quality of life in this patient group. We conducted a
multicentre, open-label randomised controlled trial. Anaemic colorectal cancer patients were randomly
allocated at least two weeks pre-operatively, to receive either oral (ferrous sulphate) or intravenous (ferric
carboxymaltose) iron. We assessed haemoglobin and quality of life scores at recruitment, immediately before
surgery and at outpatient review approximately three months postoperatively, using the Short Form 36,
EuroQoL 5-dimension 5-level and Functional Assessment of Cancer Therapy – Anaemia questionnaires. We
recruited 116 anaemic patients across seven UK centres (oral iron n = 61 (53%), and intravenous iron n = 55
(47%)). Eleven quality of life components increased by a clinically signiﬁcant margin in the intravenous iron
group between recruitment and surgery compared with one component for oral iron. Median (IQR [range])
visual analogue scores were signiﬁcantly higher with intravenous iron at a three month outpatient review (oral
iron 70, (60–85 [20–95]); intravenous iron 90 (80–90 [50–100]), p = 0.001). The Functional Assessment of
Cancer Therapy – Anaemia score comprises of subscales related to cancer, fatigue and non-fatigue items
relevant to anaemia. Median outpatient scores were higher, and hence favourable, for intravenous iron on the
Functional Assessment of Cancer Therapy –Anaemia subscale (oral iron 66 (55–72 [23–80]); intravenous iron 71
(66–77 [46–80]); p = 0.002), Functional Assessment of Cancer Therapy –Anaemia trial outcome index (oral iron
108 (90–123 [35–135]); intravenous iron 121 (113–124 [81–135]); p = 0.003) and Functional Assessment of
Cancer Therapy – Anaemia total score (oral iron 151 (132–170 [69–183]); intravenous iron 168 (160–174 [125–
186]); p = 0.005). These ﬁndings indicate that intravenous iron is more efﬁcacious at improving quality of life
scores than oral iron in anaemic colorectal cancer patients.
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Introduction
Colorectal malignancy is often associated with anaemia,
with a reported incidence of up to 40% in newly diagnosed
cases [1]. The aetiology of this anaemia is frequently due to
iron deﬁciency secondary to chronic blood loss (absolute
iron deﬁciency) or impaired utilisation of iron stores (iron
sequestration, and functional iron deﬁciency) [2, 3]. In
addition, treatment of the underlying colorectal cancer
using surgery or chemotherapy can lead to a worsening of
anaemia in these patients.
It is recognised that anaemia causes a variety of
symptoms including fatigue, lethargy and dyspnoea [4]. It
has been shown that reducing haemoglobin (Hb) levels are
associated with decreasing quality of life (QoL) scores in the
context of malignancy, and hence it has been proposed that
reversal of this anaemia will improve cancer-related QoL [4].
Furthermore, in relation to operative cases, there has been a
recent focus on standardising end points in peri-operative
medicine, with cancer-related QoL emerging as a key
patient-centric endpoint [5].
Iron replacement therapies such as oral iron are
associated with deleterious side-effects including abdominal
pain, constipation and diarrhoea. Treatment non-adherence
rates attributed to such side-effects havebeen reported tobe
in the region of 40% [6]. In addition, absorptionpathways and
access to oral iron supplementation may be impaired in
patients with malignancy [4]. Newer intravenous iron
preparations have been developed which are proposed to
offer safer, better tolerated and more efﬁcacious treatment
of iron deﬁciency anaemia [7].
We aimed to compare the QoL scores of colorectal
cancer patients who were randomly allocated to receive
either oral or intravenous iron as pre-operative treatment for
their anaemia, in order to review if either treatment
conferred an advantage in terms of improvingQoL scores.
Methods
We conducted this multicentre study in accordance with the
Declaration of Helsinki, with full ethical approval from the
National Research and Ethics Service, East Midlands,
Nottingham. We registered the study with both the MHRA
and Clinical Trials.Gov. We obtained written informed
consent fromall study participants.
We have previously reported the methods as part of a
trial comparing blood transfusion rates of anaemic
colorectal cancer treated with pre-operative oral and
intravenous iron [8]. Anaemic colorectal cancer patients
with non-metastatic disease were randomly allocated pre-
operatively in a 1:1 fashion using variable block allocation,
stratiﬁed by sex and age, to receive either oral iron (ferrous
sulphate 200 mg twice daily until surgery) or intravenous
iron (ferric carboxymaltose – Ferinject™; Vifor Pharma,
Glattbrugg, Switzerland) dosed by weight and
haemoglobin in accordance with the summary of product
characteristics. Treatment allocation was un-blinded owing
to the change in stool colour associated with oral iron
supplementation. Tominimise the risks of including patients
with non-iron deﬁciency anaemia, those with the following
conditions were not included: metastatic disease; pre-
existing haematological disease; renal failure; and those
currently undergoing chemotherapy. All patients were
included at recruitment and surgery. Only those who
underwent resectional surgery and attended the outpatient
follow-upwere included at outpatient review.
Quality of life assessments and haemoglobin
measurements were performed at the following time-
points: recruitment before iron administration; on the day of
surgery before intervention; and at their outpatient follow-
up visit between two and three months following discharge.
If an outpatient appointment was expedited due to a
complication, this appointment was not used for trial
purposes, and review was delayed until the subsequent
appointment falling within the correct 2–3-month
postoperative period. This was to ensure that all reviews
occurred at a comparable postoperative time-point.
The QoL measures we used included the EuroQoL 5-
dimension 5-level (EQ5D5L) [9] questionnaire and the
modiﬁed Short Form 36 v1 (SF36) [10] as overviews of
general well-being. These were augmented with the
Functional Assessment of Cancer Therapy – Anaemia
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(FACT-An) questionnaire [11]. This validated questionnaire
assesses speciﬁc quality of life concerns related to anaemia
and fatigue in cancer patients.
The EQ5D5L questionnaire has been widely used in
cancer and cancer-related anaemia studies [12]. Scoring
involved two components; health state description and
evaluation. For the ﬁrst component, we recorded patient-
reported scores by level of severity: a score of 1 indicates no
problems; 2, slight problems; 3, moderate problems; 4,
severe problems; and 5, extreme problems. The ﬁve
dimensions included: mobility; self-care; usual activities;
pain/discomfort; and anxiety/depression. For the second
component, we asked patients to rate their health status on
the day of the questionnaire using a 20-cm vertical scale
with end-points of 0 and 100; the point 0 corresponded to
the ‘worst health you can imagine’, and 100 corresponded
to ‘the best health you can imagine’. Missing data were not
imputed for the EQ5D5L as values obtained were not
utilised for generation of further scores.
Scoring for the SF36 form has been previously
described and validated in this patient group [13]. In total,
eight sections derive a scaled score based on the weighted
sums of the questions in that section. We then transformed
scores into a 0–100 scale, based on the assumption that
each question carried equal weight. Lower scores indicated
a higher level of disability. The eight sections included:
physical functioning; bodily pain; role limitations due
to physical health problems; role limitations due to personal
or emotional problems; emotional well-being;
social functioning; energy/fatigue; and general health
perceptions. We assessed SF36 data using the validated
software as recommended and provided by the
questionnaire developers (QualityMetric Health
OutcomesTM, SF36 Scoring Software version 4.0).
The components of the Functional Assessment of
Cancer Therapy – Anaemia (FACT-An) tool included
measures comprising 48 questions (each scored 1–4) on
Physical Well-Being, Social/Family Well-Being, Emotional
Well-Being, Functional Well-Being, and an Anaemia-
Speciﬁc Subscale. These component values were then
combined to calculate three further composite total scores:
The FACT-An Trial Outcome Index; the FACT-G (General)
and FACT-AN (Anaemia Speciﬁc). In accordance with FACT-
AN administration guidelines, subscale scores were
prorated if more than 50% of the data was available (i.e.
greater than four of the relevant seven questions answered),
but responses were excluded if they failed tomeet this level.
Derived values were only calculated if all the component
subscale values were available [14]. Additional missing data
were therefore not imputed.
The statistical level of signiﬁcance for all tests was
deﬁned as p < 0.05. We compared paired continuous data
with Student’s paired t-tests, and unpaired with Student’s t-
tests. The relationship between Hb levels and selected
components of each QoL tool was investigated to ensure
Hb change was a key causal factor underlying changes in
QoL. This has been described in previous studies for
components including SF36 Vitality [1], SF36 Physical
Component Summary [15], FACT-Trial Outcome Index [16],
FACT-Anaemia Subscale scores, FACT-G scores [1] and also
visual analogue scale equivalents [17]. These components
were used as markers of validity, and were tested using
pooled paired Hb and QoL scores at recruitment and
surgery. We excluded outpatient review values from this
process due to the potential confounding effects of
adjuvant chemotherapy. Validity was indicated by
signiﬁcant positive correlations betweenHb andQoL scores
(Pearson’s two-tailed test). We compared qualitative data
with the two-tailed Chi-squared test. We performed
statistical analyses using SPSS version 21 (SPSS, Chicago,
IL, USA).
The magnitude of clinical effects for changes in QoL
scores within each group between recruitment and the day
of surgery was calculated using effect size [18]. This
standardised measure of change was obtained by dividing
the difference between baseline and post-treatment scores
by the standard deviation of baseline scores. We
considered effect sizes of 0.2 to be small, 0.5 moderate and
0.8 large. This effect size was then used to calculate if a
minimal clinical difference (MCD) had been exceeded,
using the recognised deﬁnition of an effect size of greater
than 0.2 [18]. We then used this same deﬁnition to calculate
the Hb change that would be required to have a clinically
apparent change in QoL score. For this, all patients were
pooled to determine paired Hb and QoL scores at
recruitment and at outpatient visits, irrespective of
treatment administered, for the key variables previously
tested to assess the validity of Hb and QoL association. A
clinically-relevant response in QoL change was deﬁned as
an effect size either small (score ≥ 0.2) or moderate
(score ≥ 0.5) in magnitude [18]. Responders were deﬁned
as those who reached the threshold of the corresponding
effect size, whereas non-responders were those who failed
to reach this threshold. The mean Hb changes in those who
responded and did not respond were then calculated and
comparedwith the two-tailed Student’s t-test.
Results
We randomly allocated 61 patients to receive oral iron and
55 to intravenous iron (Fig. 1). As previously reported [8], all
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*Exclusion details: 
Haemoglobin level normal (n = 1807) Metastatic disease (n = 240) 
Not for surgery/palliative (n = 192) No Hb available at diagnosis (n = 124) 
Not adenocarcinoma (n=108) Chemo/radiotherapy as primary therapy (n = 73) 
Operation date too soon (n = 38) Medical comorbidity exclusion criteria (n = 35)
Endoscopic resection/observe (n = 8) Clinical team deemed unsuitable (n = 3)
Unable to consent (n = 2)Prisoner (n = 3)
Assessed for eligibility (n = 2762)  
Lost to follow up (n = 7) 
-Died before OPD visit (n = 4) 
-Did not attend visit (n = 3) 
Allocated to oral iron (n = 61)
-Received allocated intervention (n = 61) 
-Did not undergo surgical resection n = 4) 
Excluded (n = 2646)
-Inclusion criteria failure (n = 2633)* 
-Declined to participate (n = 10) 
-Other reasons (n = 3)
Randomised (n = 116)
Analysed:
-At surgery (n = 61) 
-At OPD (n = 50) 
Allocated to intravenous iron (n = 55)
-Received allocated intervention (n = 55) 
-Did not undergo surgical resection 
(n = 2) 
Lost to follow up (n = 11) 
-Died before OPD visit (n = 5) 
-Moved out of area (n = 2) 
-Did not attend visit (n = 4) 
Analysed:
-At surgery (n = 55) 
-At OPD (n = 42) 
Allocation
Analysis
Follow up
Enrolment
Figure 1 CONSORTdiagram for the trial. *Patients whodid not have surgical resectionwere not included in the ﬁnal outpatient
appointment. OPD, outpatients department.
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of the intravenous iron group patients received the drug
and did not receive oral iron. This study’s oral iron treatment
protocol was adhered to by 50 out of 55 (91%) patients who
did not have the date of surgery moved; no patients
randomly allocated to oral iron received intravenous iron.
Patients were well-matched across groups (Table 1).
There were no differences in any of the following measures:
baseline characteristics; initial QoL scores; baseline Hb;
haematinic levels; operative access; operation performed;
tumour stage/location; iron therapy duration; and median
time from recruitment to outpatient review (oral iron 101
(IQR 62–193[range 62–335]) days; intravenous iron 91 (48–
321 [61–135]) days, p = 0.980) [8]. One hundred and ten
patients underwent resectional surgery (oral iron n = 57
(52%), intravenous iron n = 53 (48%)) and 92 patients
attended their outpatient review (oral iron n = 50 (54%),
intravenous iron n = 42 (46%)). Hb levels were higher at
surgery, and in outpatients with intravenous iron; however,
there were no differences in blood transfusion use [8]. There
was no difference in adjuvant chemotherapy use in those
reviewed as outpatients (oral iron n = 23 (25%); intravenous
iron n = 12 (7.6%), p = 0.134).
Postoperative recovery was similar across both groups.
There were no signiﬁcant differences in complication rates
(oral iron n = 40 (70.2%), and intravenous iron n = 33
(62.3%), p = 0.381) or Clavien–Dindo grade (p = 0.995)
between recruitment and outpatient follow-up. Infective
complications were more frequent in the intravenous iron
group, with 15 patients (28%) experiencing complications
by postoperative day seven, and 21 patients (39.6%) by day
28. This compared with nine patients (15.8%) by day seven
and 14 patients (24.6%) by day 28 for oral iron. These
differences, however, were not statistically signiﬁcant
(p = 0.112 and p = 0.091, respectively), and neither was the
grade of these complications (up to day seven, p = 0.106,
and up to day 28, p = 0.083). Types of infection included:
wound (oral iron n = 11 (19%), and intravenous iron n = 15
(28%)); lower respiratory tract (oral iron n = 7 (12%), and
intravenous iron n = 11 (21%)); urinary tract (oral iron n = 9
(16), intravenous iron n = 6, 11%) and sepsis of unknown
source (oral iron n = 4 (7%), and intravenous iron n = 4
(7%)).
Mean Hb changes from recruitment to outpatient
review in relation to clinical improvements in QoL scores
Table 1 Patient baseline characteristics and operative information. Values are number,mean (SD) ormedian (IQR [range]).
Oral ironn = 61 Intravenous ironn = 55
Men 37 35
Age; years 76.5 (10.9) 73.8 (8.9)
Height;m 1.67 (9.2) 1.69 (10.3)
Weight; kg 72.7 (17.2) 79.1 (15.3)
InclusionHbg.l1 99 (11) 96 (13)
Patients receivingoral iron at recruitment 30 25
Days of iron pre-treatment, if applicable 20 (6–34 [9–151]) 27 (13–37 [6–223])
Days of study treatment 21 (15–33 [14–49]) 21 (15–34 [14–52])
ASAphysical status 1–2 43 30
Physical status ASA3–4 18 25
Cr-POSSUMmortality score at recruitment% 3.6 (2.6–9.3 [1.0–33.0]) 3.5 (2.6–6.6 [0.7–33.0])
AdjustedCharlson Score at recruitment 2.5 (1.5) 2.8 (0.9)
Nooperation performed 4 2
Laparoscopic 30 26
Converted laparoscopic 4 5
Open 23 22
Right colonic tumour 41 35
Left colonic tumour 12 11
Rectal tumour 4 7
Tumour T stage: T ≤ 2 5 8
Tumour T stage: T3 and T4 52 45
Tumour size;mm 45.5 (35–60 [15–120]) 40 (34–55 [0–90])
Blood loss;ml 100 (58–200 [20–1400]) 100 (55–390 [15–2000])
Intra-operative ﬂuid; l 1.3 (1.3) 1.1 (1.2)
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and effect size are illustrated in Table 2. When we
compared scores for all components which showed a
signiﬁcant intragroup change from recruitment to surgery,
only one component in the oral iron group was of a
magnitude tomeet a minimal clinically important difference
(i.e. effect size > 0.2). This compared with 11 patients in the
intravenous iron group (see Table 3). On review of the
entire cohort at recruitment and on the day of surgery, the
Hb level at each time-point was positively correlated with
the following QoL scores: FACT-Trial Outcome Index
(R = 0.416, p = 0.002); FACT-G (R = 0.234, p = 0.013);
FACT-An Anaemia Subscale (R = 0.279, p = 0.011);
EQ5D5L visual analogue scale (R = 0.251, p = 0.001); SF36
Physical Component Summary (R = 0.227, p = 0.003); and
SF36 Vitality (R = 0.252, p = 0.001). The results of some of
these scores are reported below.
In the intravenous iron group, all components of the
FACT-An score increased signiﬁcantly during at least one
inter-visit period, with the exception of social well-being,
and six of the eight components increased from both
recruitment to surgery and from surgery to outpatient
review. Despite the general trend for increases in each
component score noted in both groups throughout the
study period, these increases were only signiﬁcant for one
component at one time period for oral iron (Fig. 2). Median
(IQR [range]) intravenous iron scores were signiﬁcantly
Table 2 Comparison of mean haemoglobin changes between those who did and did not have a clinical quality of life
improvement from recruitment to outpatient review. Values are mean (SD). Effect size [18] was calculated by dividing the
difference between baseline and post-treatment scores by the standard deviation of baseline scores, where effect sizes of > 0.2
were regarded to be small, > 0.5 moderate and > 0.8 large. Responders are those who reached the threshold of the speciﬁed
effect size. Non-responders failed to reach the speciﬁed effect size.
Component Gradeof effect size Group Hbchangeg.l1 p value
EQ5D5L visual analogue scale Mild Responders 30.6 (17.9) 0.016
Mild Non-responders 20.9 (16.8)
Moderate Responders 33.4 (17.0) 0.002
Moderate Non-responders 20.8 (17.0)=112)
SF36 vitality Mild Responders 28.8 (18.3) 0.126=112)
Mild Non-responders 22.6 (17.0)=112)
Moderate Responders 31.3 (17.1) 0.026=112)
Moderate Non-responders 22.2 (17.6)
SF36mental component summary Mild Responders 29.7 (19.4) 0.017
Mild Non-responders 19.4 (10.7)
Moderate Responders 30.5 (19.7) 0.020
Moderate Non-responders 20.9 (12.8)
SF36physical component summary Mild Responders 29.7 (17.2) 0.108
Mild Non-responders 23.1 (17.9)
Moderate Responders 30.9 (18.0) 0.078
Moderate Non-responders 23.4 (17.2)
FACT-An anaemia subscale Mild Responders 26.0 (17.5) 0.311
Mild Non-responders 21.3 (17.1)
Moderate Responders 26.8 (19.2) 0.246
Moderate Non-responders 21.8 (14.9)
FACT-An trial outcome index Mild Responders 23.8(17.4) 0.968
Mild Non-responders 23.6 (17.55)
Moderate Responders 24.6 (18.1) 0.648
Moderate Non-responders 22.3 (16.3)
FACT-G Mild Responders 26.0 (17.4) 0.252
Mild Non-responders 20.3 (16.7)
Moderate Responders 25.7 (17.1) 0.445
Moderate Non-responders 22.1 (17.6)
EQ5D5L, EuroQoL 5-dimension 5-level questionnaire; SF36, modiﬁed Short Form 36 v1 questionnaire; FACT-AN, Functional
Assessment of Cancer Therapy –Anaemia questionnaire.
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higher than oral iron responses at outpatient follow-up for
emotional well-being (oral iron 21 (20–22 [7–24]);
intravenous iron 22 (21–24 [10–28]), p = 0.033); functional
well-being (oral iron 22 (15–25 [9–28]); intravenous iron 26
(23–28 [12–28]), p = 0.001); FACT-An subscale (oral iron 66
(55–72 [23–80]); intravenous iron 71 (66–77 [46–80]),
p = 0.002), FACT-An trial outcome index (oral iron 108 (90–
123 [35–135]); intravenous iron 121 (113–124 [81–135]),
p = 0.003) and FACT-An total score (oral iron 151 (132–170
[69–183]); intravenous iron 168 (160–174 [125–186]),
p = 0.005).
Intra-group changes in each component of EQ5D5L are
illustrated in Fig. 3. Median visual analogue scores were
signiﬁcantly higher with intravenous iron than with oral iron
at outpatient review (oral iron 70, (60–85 [20–95]);
intravenous iron 90 (80–90 [50–100]), p = 0.001).
Within the oral iron group, only the mental component
summary score of the SF36 between surgery and outpatient
review showed a signiﬁcant increase (p = 0.041). In
contrast, within the intravenous iron group, all factors
signiﬁcantly increased between surgery and outpatients:
Physical Functioning mean difference (MD) 10.52,
(p = 0.04); Role Limitation due to emotion MD 23.89,
(p = 0.020); Role Limitation due to pain MD 33.33,
(p = 0.004); General Health MD 8.68, (p = 0.005); Vitality
MD 18, (p = 0.001); Social Functioning MD 17.08,
(p = 0.008); Mental Health MD 10.8, (p = 0.001); Physical
Component Summary MD 5.7,(p = 0.003); Mental
Component Summary MD 7.36, (p = 0.001) and Bodily Pain
MD 15.56, (p = 0.002). Furthermore, General Health MD
3.25, (p = 0.049), Mental Component Score MD 2.85,
(p = 0.018); Vitality MD 13.22, (p = 0.001) and Social
Functioning MD 7.09, (p = 0.005) also increased
signiﬁcantly from recruitment to surgery. Signiﬁcant
differences were evident between groups at outpatient
review in all bar two of the SF36 components, as illustrated
in Table 4.
Discussion
We found that intravenous iron resulted in a faster clinically
evident increase in QoL scores than oral iron, and may be
more efﬁcacious at improving QoL scores in anaemic
colorectal cancer surgical patients. The differences seen
weremost profound over a longer duration from initiation of
treatment, which is expected given the lag between
intravenous iron administration and response, as noted in
previous trials [19]. Despite this, the signiﬁcant clinical effect
of intravenous iron was also evident after short periods of
pre-operative optimisation. This beneﬁt of intravenous iron
was not solely limited to the speciﬁc symptomatology of
anaemia but was also evident across generic measures of
well-being. We believe that it is most likely that the
Table 3 Evaluation ofmagnitude of clinical effect for component scoreswhich increased signiﬁcantly between recruitment and
day of surgery. Effect size [18] was calculated by dividing the difference between baseline and post-treatment scores by the
standard deviation of baseline scoreswhere grading of effect sizes of > 0.2were regarded to be small, > 0.5moderate and > 0.-
8 large.
QoL Component Group
Recruitment to dayof
surgery change (score) SD Effect size Effect grade
FACT-AN Physical well-being iv iron 2.5 5.47 0.46 Small
Functional well-being iv iron 3.87 6.52 0.59 Moderate
Anaemia subscale iv iron 9 16.14 0.56 Moderate
Trial outcome index iv iron 15.3 24.96 0.61 Moderate
FACT-G iv iron 7.1 13.01 0.55 Moderate
FACT-total iv iron 7.1 27.24 0.26 Small
EQ5D5L Mobility Oral iron 0.31 1.08 0.29 Small
Self-care iv iron 0.08 0.51 0.16 NCD
Pain anddisability iv iron 0.47 1.01 0.47 Small
Visual analogue score iv iron 8.4 19.93 0.42 Small
SF36 General health iv iron 3.25 20.26 0.16 NCD
Vitality iv iron 13.22 23.79 0.56 Moderate
Social functioning iv iron 7.09 29.49 0.24 Small
Mental component summary iv iron 2.85 9.34 0.31 Small
EQ5D5L, EuroQoL 5-dimension 5-level questionnaire; SF36, modiﬁed Short Form 36 v1 questionnaire; FACT-AN, Functional
Assessment of Cancer Therapy –Anaemia questionnaire; iv, intravenous iron; NCD, no clinical difference.
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improvements in QoL were secondary to more efﬁcacious
treatment of anaemia. Intravenous iron is thought to
produce more rapid and greater rises in Hb levels than oral
iron [8, 20–22], and as demonstrated in the present study,
QoL scores were closely correlated with absolute Hb values.
This is further supported by a lack of other key confounders
which may inﬂuence QoL including operative access and
adjuvant therapy.
Our results show that only the intravenous iron group
showed signiﬁcant changes in QoL scores between
recruitment and day of surgery, whichmet aminimal clinical
difference. Based on the deﬁnition of effect size, ‘small’
improvements were seen in seven components across
broad aspects of QoL, with anaemia-speciﬁc components
showing ‘moderate’ improvements. The literature argues
that a moderate effect size (> 0.5) is required to
demonstrate a signiﬁcant clinical change in QoL [18, 23].
This threshold of discrimination for changes in health-
related quality of life has been validated clinically [23], and is
based on the psychological assessment of the limits of
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Figure 2 FACT-Anmean scores at each time-point for (a) oral iron and (b) intravenous iron. Recruitment ; Day of surgery ;
Outpatient Department appointment ; PWB, PhysicalWell-being; SWB, Social/FamilyWell-being; EWB, EmotionalWell-being;
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human discrimination [24]. Measures of Vitality (SF36),
Functional Well-Being and speciﬁc scores of anaemia
symptomatology (FACT-AN) still met this higher threshold
of MCD, and hence changed signiﬁcantly even over the
short period from recruitment to day of surgery. These
components would appear to be closely linked to anaemia
and thus alsoHb levels (Table 2).
The QoL tools employed requested patients to report
their QoL over periods ranging from 1–4 weeks.
Considering that the initial time period of iron treatment
from recruitment to surgery was in the order of 3 weeks,
there would have been a degree of overlap of the pre-
treatment period when QoL was reported on the day of
surgery, leading to perhaps an underestimation of the
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Figure 3 Changes in EQ5D5L component scores at each time-point for (a) oral iron and (b) intravenous Iron and (c) visual
analogue scale scores. Recruitment ; day of surgery ;Outpatient Department appointment;MOB,Mobility; SC, Self-care;
US, Usual Activity; PD, Pain andDisability; AD, Anxiety andDepression; VAS, visual analogue scale. *Signiﬁcant change in
p < 0.05 and **of p < 0.01. Error bars display 95%CI.
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Table 4 SF36 component scores at review in each group. Values aremean (SD) ormedian (IQR [range]). p values below scores
denote intra-group differences from the previous time-point, and p values in the right columndenote inter-groupdifferences
between oral and intravenous iron at each time-point.
Field Time Oral iron Intravenous iron
Oral vs.
intravenous
p value
Physical
functioning
Recruitment 65 (31–85 [0–100]) 60 (20–84 [0–100]) 0.589
Day of surgery 65 (40–85 [10–100])
p = 0.735
65 (30–90 [10–100])
p = 0.154
0.887
Outpatient 70 (32–87 [0–96])
p = 0.237
74 (45–95 [0–100])
p = 0.041
0.377=112)
Role limitation
due to pain
Recruitment 25 (0–100 [0–100]) 12.5 (0–100 [0–100])) 0.713
Day of surgery 25 (0–100 [0–100])
p = 0.924
50(0–100 [0–100])
p = 0.297
0.34
Outpatient** 25(0–100 [0–100])
p = 0.502
100 (50–100 [0–100])
p = 0.004
0.01
Bodily pain Recruitment 72 (51–100 [0–100]) 68 (41–100 [12–100]) 0.981
Day of surgery 72 (46–92 [0–100])
p = 0.641
80 (51–100 [22–100])
p = 0.056
0.3
Outpatient 74 (52–100 [31–100])
p = 0.053
84 (74–100 [2–100])
p = 0.001
0.229
General health Recruitment 57 (46–72 [15–92]) 55 (45–77 [20–95]) 0.776
Day of surgery 62 (50–77 [27–92])
p = 0.112
63 (52–77 [25–90]))
p = 0.049
0.758
Outpatient** 62 (50–77 [10–92])
p = 0.652
77 (65–86 [45–100]))
p = 0.005
0.002
Vitality Recruitment 47 (24) 44 (24) 0.625
Day of surgery * 52 (21)
p = 0.177
59 (22)
p = 0.001
0.048
Outpatient** 59 (19)
p = 0.065
72 (16)
p = 0.001
0.00
Social
functioning
Recruitment 75 (50–86 [25–100]) 63 (34–88 [0–100])) 0.159
Day of surgery 62.5 (50–100 [0–100])
p = 0.716
75 (50–100 [0–100]))
p = 0.005
0.349
Outpatient* 75 (50–100 [0–100])
p = 0.391
100 (88–100 [25–100])
p = 0.008
0.03
Role limitation
due to emotion
Recruitment 57 (44) 61 (47) 0.849
Day of surgery 68 (44)
p = 0.631
60 (46)
p = 0.202
0.261
Outpatient* 74 (43)
p = 0.230
80 (37)
P = 0.020
0.03
Mental health Recruitment 76 (65–87 [44–100]) 76 (64–88 [12–100])) 0.947
Day of surgery 78 (64–89 [40–100])
p = 0.539
80 (72–92 [24–100]))
p = 0.080
0.178
Outpatient** 84 (72–92 [20–100])
p = 0.093
92 (88–92 [56–100])
p = 0.001
0.00
Physical component
summary
Recruitment 42 (11) 41 (11) 0.71
Day of surgery 43 (10)
p = 0.915
43 (11)
p = 0.060
0.678
Outpatient 43 (9)
p = 0.889
47 (9)
p = 0.003
0.119
(continued)
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treatment effect for both treatments. If indeed Hb levels
were closely linked to QoL scores as suggested by the
present study, then such an underestimate of clinical effects
would be further evident in the more efﬁcacious treatment
of anaemia which recent data indicate is attributed to
intravenous iron. This may account for why, although
clinically-relevant increases in scores were seen with
intravenous iron at the point of surgery, few scores were
signiﬁcantly higher than thosewithin the oral iron group.We
also acknowledge that current recommendations suggest
at least a three-week timeframe for haemoglobin
incrementation with intravenous iron administration [25].
Likewise, oral iron was given over a similar timescale, and in
both cases the treatment effect may have been
underestimated. However, our trial was designed to be
pragmatic and applicable to current cancer treatment
timelines. It must be acknowledged that in some European
countries the timing of surgery for malignancy is subject to
legal regulations [26]. Consequently, a balance between
timely cancer treatment, haemoglobin improvement and
quality of life is needed. Therefore, the constraints of the
clinical timelinewere factored into the trial design.
It must be re-emphasised that in the current
randomised controlled trial, the study was powered to
detect a difference in transfusion rates, and not for QoL
as the primary outcome measure. QoL outcomes were
speciﬁed as secondary outcomes in the original trial
design, and we, therefore, acknowledge that further
studies powered to analyse QoL outcomes are required
to validate these ﬁndings. Furthermore, due to difﬁculties
in concealing oral iron administration from patients due
to stool discoloration [27], the study was not blinded by
design. This does leave our study vulnerable to the
placebo effect, and the inﬂuence of patient beliefs on
QoL perception. In addition, questionnaires were
distributed at follow-up between two and three months
following surgery. Quality of life can change over time,
and this may have, therefore, inﬂuenced patient-reported
scores. There were, however, no signiﬁcant differences in
mean time to postoperative follow-up between the two
groups.
Haemoglobin was positively correlated with six
subscales across all three QoL questionnaires. Although we
found that the correlation was modest, it is important to
acknowledge that there are a multitude of factors
inﬂuencingQoL. Therefore, it could be argued that over this
timescale, the improvements in QoL scores seen with Hb
changes as a discrete factor emphasise the clinical
importance of treating anaemia in this patient group. On
review of the entire cohort, it appeared that as Hb increases
approached the 30 g.l1 increment, small improvements in
QoL scores were evident, which rose to a moderate clinical
effect when changes exceeded this mark. This could be
used as a target for both future research and in clinical
practice to guide therapy in this patient population.
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